These results provide important information about the emerging role of SMARCA4 in sinonasal cancers and particularly suggest that TCS is on a spectrum with SMARCA4-deficient sinonasal carcinomas and could benefit from similar novel targeted therapies [95]. This evidence concerns the gene SMARCA4 and nasal cavity and paranasal sinus carcinoma.